Qiagen N.V. Common Shares (QGEN)

FairStock Score: 60/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I am looking for businesses that are understandable, durable, and bought at a sensible price. Qiagen is understandable enough: it sells sample-to-insight tools and consumables for molecular diagnostics and research, with 5,500 employees and a global footprint. The latest reported quarter, fiscal Q2 2026, produced $535.0M of revenue and $103.4M of net income, a 19.33% net margin, which tells me the business is profitable. Financial health is reasonable: FairStock data show debt-to-equity of 0.49, Altman Z-Score 2.90, Piotroski F-Score 7/9, and trailing free cash flow of $440.6M, a 5.7% FCF yield. But quality is not the same as cheapness. At the 2026-10-13 close of $45.44, FairStock calculates P/E 23.07, P/B 2.79, EV/EBITDA 12.31, PEG 3.10, ROE 11.93%, and ROCE 5.87%. The Graham Number is $26.85, leaving a negative margin of safety of -69.24%. Growth is uneven: the supplied growth figures show revenue growth of 0.28% and profit growth of 7.43%, while the latest quarter margin was healthy. FairStock's score is 60/100, and its Lynch category is none because only 0 years of filed results exist and three are needed. I would call this a decent, cash-generative healthcare supplier, but the price already reflects a lot of optimism. I prefer a larger discount to intrinsic value and clearer growth before getting excited.

In plain English: Qiagen makes lab tools and tests that help researchers and doctors turn biological samples into medical insights. In its latest reported quarter, fiscal Q2 2026, it earned $103.4 million on $535.0 million of revenue, but sales growth looks slow and the business earns only a modest return on the money it invests. At $45.44 a share, the stock looks expensive compared with several standard value checks, even though the company is profitable and generates cash.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer